Press Releases
Date Title and Summary View
Jan 9, 2012 Once-daily ACH-1625 safe, well-tolerated and achieves 100% cEVR after 12 weeks of treatmentPilot study of ACH-1625 in HCV genotype 3 achieves maximal 3.68 log10 reductionACH-2684 safe, well tolerated and achieves HCV genotype 1 maximal 4.63 log10 reduction; Additional dosing on-going NEW HAVEN, Conn., Jan. 9, 2012 (GLOBE NEWSWIRE) -- Achillion ...
Jan 4, 2012 NEW HAVEN, Conn., Jan. 4, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, announced today the receipt of a Fast Track designation from the U.S. Food and Drug Administration (FDA) for ACH-1625 for the treatmen...
Dec 5, 2011 NEW HAVEN, Conn., Dec. 5, 2011 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported proof-of-concept data from its Phase 1b clinical trial of ACH-2928, a first-generation NS5A inhibitor, demonstrating th...
Nov 21, 2011 NEW HAVEN, Conn., Nov. 21, 2011 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that members of the Company's executive team will present at the upcoming 23rd Annual Piper Jaffray Health Care Confe...
Nov 8, 2011 NEW HAVEN, Conn., Nov. 8, 2011 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three and nine months ended September 30, 2011. For the third quarter of 2011, Achillion repo...
Nov 3, 2011 NEW HAVEN, Conn., Nov. 3, 2011 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Dr. Milind Deshpande, President of Research and Development and Chief Scientific Officer, will provide a corporat...
Oct 13, 2011 NEW HAVEN, Conn., Oct. 13, 2011 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced the nomination of an additional clinical candidate for the treatment of the hepatitis C virus (HCV) from its NS5A inh...
Oct 3, 2011 NEW HAVEN, Conn., Oct. 3, 2011 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that four abstracts on HCV compounds discovered and developed by Achillion were accepted for presentation at the 62nd ...
Sep 22, 2011 NEW HAVEN, Conn., Sept. 22, 2011 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, President and Chief Executive Officer, will provide a corporate update at the upcoming Si...
Aug 31, 2011 NEW HAVEN, Conn., Aug. 31, 2011 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that members of the executive team will present at the following upcoming investor conferences: Stifel Nicholas ...
FirstPrevious ...
7
... NextLast
Add to Briefcase = add release to Briefcase

built@zoomedia
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue